Brief: Pasithea Completes Enrollment, Dosing of First Cohort in PAS-004 Phase 1/1B NF1 Trial
31/07/2025 13:22
July 31 (Reuters) - Pasithea Therapeutics Corp KTTA.O: PASITHEA THERAPEUTICS COMPLETES ENROLLMENT AND INITIAL DOSING OF FIRST COHORT FROM ITS PHASE 1/1B CLINICAL TRIAL OF PAS-004 IN ADULT NF1 PATIENTS Source text: ID:nGNXQqjP6 Further company coverage: KTTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement